How the ‘Cancer Moonshot’ Initiative Sparks Promising Investment in Cancer Therapeutics

The dawn of the Cancer Moonshot initiative by President Joe Biden has spurred a wave of promising advancements in cancer treatments and research. Reigniting the mission launched in 2016, the Biden-Harris administration aims to reduce cancer death rates by at least 50% over the next quarter-century. The initiative's ambitious goal, combined with the current advancements in cancer therapeutics and diagnostics, paints a hopeful landscape for retail investors interested in the cancer space.

Looking at the overall global cancer diagnostics and treatment market size, it is estimated to be US$220.3 billion in 2023, with a projected growth to US$470.61 billion by 2032. This marks a CAGR of 8.8%, revealing an encouraging prospect for potential investors.

Consider this - the cancer diagnostic segment alone accounted for 46.8% of the total market share in 2021. Furthermore, the hospital segment is projected to grow at a impressive Compound Annual Growth Rate (CAGR) of 10.9% from 2023 to 2032. Thus, the expansion of the cancer therapeutics and diagnostic markets presents a timely investment opportunity.

As for the cancer treatment segment, it accounted for around 56% of the global oncology market share in 2020. About 19.3 million new cancer cases and 10 million deaths were registered the same year. However, the alarming rise in cancer cases, expected to surge by 47% from 2020 to 2040, calls for urgent advancements in cancer therapeutics and diagnostics. This, in turn, points towards substantial growth in the cancer treatment market.

According to a report from Coherent Market Insights, the global cancer therapy market was estimated to be valued at US$184.8 billion in 2022, and expected to grow at a CAGR of 8.4% through to 2030—where it would surpass US$353.billion.

Breast cancer’s growth potential is further underlined by a forecast from Spherical Insights, projecting the global breast cancer market size to escalate from US$31.9 billion in 2022 to US$85.5 billion by 2032. This represents an impressive CAGR of 10.3%.

One of the integral components of the Cancer Moonshot initiative is the early diagnosis of cancer. The introduction of new technologies and rigorous clinical trials, like blood tests, is a significant leap in this direction. Likewise, mRNA technology, widely recognized for its role in developing COVID-19 vaccines, could potentially play a pivotal role in preventing cancer cells.

The investment landscape is also broadening, with North America reaching 46.2% of the total market share in 2021, followed closely by the fast-growing European market. In the past five years, 64 new oncology active substances have been launched globally, underscoring the robust advancements in the field.

In the realm of cancer drugs, there is significant growth as well. The global metastatic cancer drugs market was valued at $67.7 billion in 2022, and it's expected to reach $136.9 billion by 2032, exhibiting a CAGR of 7.3%. Furthermore, the oncology drugs market is estimated to grow at a CAGR of 11.99% between 2022 and 2027, promising even more lucrative returns on investments.

All these impressive figures illuminate the potential of investing in the cancer space. This is catalyzed by President Biden's revitalized Cancer Moonshot initiative, which, in its quest to improve cancer treatment and diagnosis, opens up promising investment opportunities. Retail investors, therefore, can seize this moment to contribute to a life-saving cause while realizing significant returns on their investments.

While each investment carries its own risk, the stakes are especially high in the healthcare sector, where companies face a difficult path from laboratory breakthroughs to successful commercialization. This pathway, full of potential roadblocks from clinical trial failures to regulatory obstacles, makes the healthcare sector a challenging, yet potentially rewarding field for investors.

For those who choose to invest in oncology, they are not only funding innovations that may lead to improved treatments and patient outcomes, but they are also potentially laying a foundation for robust returns on investment. Even so, those returns are by no means guaranteed, and it is critical to remember that investment in this sector should not be made lightly.